NICE is evaluating the use of pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2 positive metastatic or locally recurrent unresectable breast cancer, which has not been previously treated, or has relapsed after adjuvant therapy. The guidance is at an early stage of development and its publication date is yet to be confirmed.